AOD-9604 (Advanced Obesity Drug) is a modified fragment of human growth hormone (HGH), specifically amino acids 176-191. It was originally developed as an anti-obesity drug by Monash University in Australia.
AOD-9604 retains the fat-reducing activity of HGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without affecting blood sugar levels or causing cellular proliferation.
AOD-9604 received GRAS (Generally Recognized As Safe) status from the FDA as a food supplement ingredient. However, it is not FDA-approved as a drug. It is available through compounding pharmacies for off-label use in weight management protocols.
Clinical trials showed modest fat loss effects; it is often used as part of comprehensive weight management protocols.
AOD-9604 mimics the lipolytic fragment of growth hormone:
Its selectivity for fat metabolism without broader GH effects makes it a targeted approach to fat loss.
Study demonstrating that AOD-9604 stimulated lipolysis and inhibited lipogenesis in obese mouse models without affecting IGF-1 levels.
Phase 2 clinical trial evaluating oral AOD-9604 in obese subjects, showing fat loss without adverse effects on glucose metabolism.
Research showing AOD-9604 promoted cartilage repair and regeneration, suggesting applications beyond weight management.
If you're using a browser with advanced ad blocking security measures, the above study links may not work. You can copy the link and paste it into a new window.
Disclaimer: The information on this page was generated with the assistance of artificial intelligence and compiled from publicly available sources. While efforts are made to ensure accuracy, information may be incomplete, outdated, or incorrect and should not be relied upon as medical advice.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded drugs have not been approved by the FDA; have not been reviewed by the FDA for safety, efficacy, or quality; and have not been demonstrated to the FDA to be safe or effective for their intended use. The processes by which the compounded drugs are manufactured have not been reviewed by the FDA. FDA approved products containing semaglutide and tirzepatide are available.